Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015841
Chunk: 240

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 240
---
4,164,323 |   |     |   |  1,719,338 |   |
| Cash and cash equivalents, end of the period                                |   |                 9,669,546 |   |     |   |  8,408,199 |   |
| Supplemental disclosure of non-cash investing and financing activities:     |   |                           |   |     |   |            |   |
| Right-of-use assets obtained in exchange for lease liabilities              | $ |                         - |   |     |   |    356,805 |   |
| Issuance costs included in accounts payable                                 | $ |                   271,618 |   |     |   |          - |   |
| Deferred issuance costs on issued shares related to SEPA                    | $ |                   300,000 |   |     |   |          - |   |

<div align='center'>The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

F-29

MEDICUS PHARMA LTD.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)</div>

1.Description of business

Medicus Pharma Ltd. (the "Company"), formerly Interactive Capital Partners Corporation, is a clinical stage, multi-strategy, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets.

The Company is a public limited Company originally incorporated pursuant to the provisions of the Business Corporations Act (Ontario) on April 30, 2008, as a private company named Interactive Capital Partners Corporation, with nominal assets and liabilities. The Company's registered office is located at 100 King Street West, Suite 3400, One First Canadian Place, Toronto, Ontario, Canada, and its head office is located at 300 Conshohocken State Rd., Suite 200, W. Conshohocken, PA.

Reverse Share Split

On June 25, 2024, the Company's shareholders approved an amendment to the Company's articles of incorporation to provide for the share consolidation, or reverse share split, of the Company's issued and outstanding common shares at such a consolidation ratio to be determined by the Board of Directors of the Company in its sole discretion, to permit the Company to satisfy all conditions and necessary regulatory approvals to list the common shares on a U.S. national securities exchange as the Board of Directors of the Company may determine in its sole direction (